Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists in Private Practice in the U.S.

Articles with lock require a subscription to GLG News | Request a free trial
July 2, 2008
Pharma may benefit from both new drugs and new uses for old drugs
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: GLG Expert Contributor
The public benefits when new uses are found for old drugs.  The benefit comes more quickly as the pharma company does not need to go through as many early studies to allow the approval for the drug use. However, I believe that pharma realizes that new uses for old drugs is not the way...
June 24, 2008
Molecular Profiling for Epo Stimulating Agents: Trying to 'Stop the Bleeding'
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: GLG Expert Contributor
Use of Epo Stimulating Agents (ESAs) for cancer patients have all but come to a screeching halt when a plattoon of studies came out suggesting that ESAs might actually cause more harm, notably by possibly acting as a growth factor for tumor cells.  Now, reserachers are trying to determine...
June 6, 2008
Transgene's TG4010 Vaccine for Lung Ca - Add it to the List...
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial | www.pipelinereview.com
Author: GLG Expert Contributor
Transgene's TG4010 vaccine has a fairy elegant two-gene design.  It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer.  More mature survival data will be ready by year's end.  Phase III study is being planned.  ...
June 4, 2008
Antisoma's ASA404: Another Anti-Angiogenesis Agent to Watch
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
Adding novel biologic agents (such as ASA404) to traditional chemotherapy is a very hot trend in cancer research.  The data from Antisoma's lung cancer study are certainly intriguing, but again, phase II, and retrospective. 
June 3, 2008
Genentech’s Avastin Appears Safe in Early Colon Cancer
Analysis of: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. | www.abstract.asco.org
Author: GLG Expert Contributor
While chemo plus Avastin is the standard of care for first treatment of advanced colon cancer, chemotherapy alone is used for most early colon cancer. This large study demonstrates the relative safety of adding Avastin to chemo in the early - adjuvant – setting.
June 3, 2008
Continuing Genentech's Herceptin - Confirming What We Suspected
Analysis of: Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Many of us oncologists have been in the practice of continuing  Herceptin (Trastuzumab) even when the breast cancer we were treating was growing while on the drug.  Now, this randomized study gives data to back up that practice.
June 2, 2008
Can Glaxo’s Affymetrix Microarray Predict Who Will Benefit from its MAGE-A3 Immunotherapy?
Analysis of: New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma | www.pipelinereview.com
Author: GLG Expert Contributor
This describes a potential two-step process using modern molecular biology to customize cancer therapy. First the Affymetrix Microarray analyzes tumor genes to try to identify which patients are at high risk to have a cancer recurrence following lung cancer surgery. Second, Glaxo's MAGE-A3 proprietary...
May 29, 2008
Glaxo's Promacta Hits a Snag with the FDA
Analysis of: FDA says Glaxo drug fails to control bleeding | seattletimes.nwsource.com
Author: GLG Expert Contributor
Apparently, the FDA was not impressed enough with the data for Promacta (eltrombopag) for the treatment of ITP, a common and potentially serious auto-immune bleeding disorder involving platelets.  Citing a lack of "robust evidence" from several studies, the FDA will be seeking further opinions...
Brian AbbottMay 19, 2008
TREANDA for CLL could be a winner
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
Brian AbbottMay 19, 2008
National healthcare? Better find a new pool of physicians
Analysis of: Look to England's example for ways to solve America's health-care problem | www.sltrib.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?

Previous Page : 1 2 3 4 5 6 Next11 to 20 of 55

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617